KALV — Kalvista Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Kalvista Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 April 30th | 2023 April 30th | 2024 April 30th | 2025 April 30th | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 8 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-KT |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 49.1 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 46 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 96.6 | 111 | 140 | 188 | 161 |
| Operating Profit | -96.6 | -111 | -140 | -188 | -112 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -82.3 | -92.9 | -127 | -180 | -111 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -82.3 | -92.9 | -127 | -183 | -110 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -82.3 | -92.9 | -127 | -183 | -110 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -82.3 | -92.9 | -127 | -183 | -110 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.36 | -3.33 | -3.44 | -3.69 | -2.03 |
| Dividends per Share |